T0	KEYPHRASE-NOTYPES 3 13	many areas
T1	KEYPHRASE-NOTYPES 21 34	United States
T2	KEYPHRASE-NOTYPES 69 70	B
T3	KEYPHRASE-NOTYPES 97 108	New England
T4	KEYPHRASE-NOTYPES 114 133	mid-Atlantic states
T5	KEYPHRASE-NOTYPES 135 144	Minnesota
T6	KEYPHRASE-NOTYPES 150 159	Wisconsin
T7	KEYPHRASE-NOTYPES 170 175	areas
T8	KEYPHRASE-NOTYPES 181 185	risk
T9	KEYPHRASE-NOTYPES 189 198	infection
T10	KEYPHRASE-NOTYPES 207 221	prolonged bite
T11	KEYPHRASE-NOTYPES 253 257	Risk
T12	KEYPHRASE-NOTYPES 261 270	infection
T13	KEYPHRASE-NOTYPES 305 326	western United States
T14	KEYPHRASE-NOTYPES 353 357	risk
T15	KEYPHRASE-NOTYPES 361 373	transmission
T16	KEYPHRASE-NOTYPES 377 378	B
T17	KEYPHRASE-NOTYPES 399 414	unengorged tick
T18	KEYPHRASE-NOTYPES 427 438	spirochetes
T19	KEYPHRASE-NOTYPES 456 461	hours
T20	KEYPHRASE-NOTYPES 470 474	bite
T21	KEYPHRASE-NOTYPES 495 503	tick gut
T22	KEYPHRASE-NOTYPES 511 526	salivary glands
T23	KEYPHRASE-NOTYPES 553 560	factors
T24	KEYPHRASE-NOTYPES 562 592	routine antibiotic prophylaxis
T25	KEYPHRASE-NOTYPES 628 643	engorged Ixodes
T26	KEYPHRASE-NOTYPES 673 680	patient
T27	KEYPHRASE-NOTYPES 687 699	endemic area
T28	KEYPHRASE-NOTYPES 701 711	local rate
T29	KEYPHRASE-NOTYPES 715 724	infection
T30	KEYPHRASE-NOTYPES 728 733	ticks
T31	KEYPHRASE-NOTYPES 739 740	B
T32	KEYPHRASE-NOTYPES 770 774	tick
T33	KEYPHRASE-NOTYPES 809 814	hours
T34	KEYPHRASE-NOTYPES 818 841	single 200-mg oral dose
T35	KEYPHRASE-NOTYPES 845 856	doxycycline
T36	KEYPHRASE-NOTYPES 887 892	hours
T37	KEYPHRASE-NOTYPES 899 906	removal
T38	KEYPHRASE-NOTYPES 914 918	tick
T39	KEYPHRASE-NOTYPES 923 934	prophylaxis
T40	KEYPHRASE-NOTYPES 943 955	Lyme disease
T41	KEYPHRASE-NOTYPES 964 975	Prophylaxis
T42	KEYPHRASE-NOTYPES 1022 1026	bite
T43	KEYPHRASE-NOTYPES 1038 1048	local rate
T44	KEYPHRASE-NOTYPES 1052 1061	infection
T45	KEYPHRASE-NOTYPES 1067 1068	B
